Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

GLICLAZIDE

18 general benefit · 1 not a benefit

Other products in the same Health Canada class (A10B, A10BB) — coverage varies; not interchangeable

  • Glyburide (Apo-Glyburide): general benefit, Not a benefit
  • Glimepiride (Amaryl): not a benefit
  • Canagliflozin (Invokana): general benefit
  • Dapagliflozin (Forxiga): general benefit
  • Dapagliflozin + metformin (Xigduo): general benefit
  • Empagliflozin (Jardiance): general benefit

12 more in the class list below

Apo-Gliclazide MR · DIN 02297795 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Gliclazide MR · DIN 02297795 Manufacturer: Apotex Inc.; listing date 2008-08-28 Health Canada: Marketed since 2014-12-12 · brand APO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78313 · Verify on the e-Formulary ↗ (DIN 02297795)

Source record
DIN 02297795: Apo-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id APX Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02297795 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78313
Interchangeable products
Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended 2025-03-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02297795
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diamicron MR · DIN 02242987 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Diamicron MR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Diamicron MR · DIN 02242987 Manufacturer: Servier Canada Inc.; listing date 2007-04-02 Health Canada: Marketed since 2001-04-04 · brand DIAMICRON MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Servier canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66827 · Verify on the e-Formulary ↗ (DIN 02242987)

Source record
DIN 02242987: Diamicron MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SEV Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.1660; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242987 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66827
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended 2024-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02242987
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Gliclazide MR · DIN 02429764 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Gliclazide MR · DIN 02429764 Manufacturer: Jamp Pharma Corporation; listing date 2015-05-28 Health Canada: Marketed since 2024-10-04 · brand JAMP GLICLAZIDE-MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91420 · Verify on the e-Formulary ↗ (DIN 02429764)

Source record
DIN 02429764: Jamp Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id JPC Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429764 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91420
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended 2025-11-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429764
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Gliclazide MR · DIN 02423286 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Gliclazide MR · DIN 02423286 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2014-11-27 Health Canada: Marketed since 2014-06-02 · brand MINT-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90799 · Verify on the e-Formulary ↗ (DIN 02423286)

Source record
DIN 02423286: Mint-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id MIN Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423286 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90799
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended 2024-11-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423286
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Gliclazide MR · DIN 02438658 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Gliclazide MR · DIN 02438658 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2020-10-30 Health Canada: Marketed since 2015-08-07 · brand MYLAN-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92302 · Verify on the e-Formulary ↗ (DIN 02438658)

Source record
DIN 02438658: Mylan-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id MYL Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02438658 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92302
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: resolved shortage (ended 2025-08-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02438658
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Gliclazide MR · DIN 02463571 · 30mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Gliclazide MR · DIN 02463571 Manufacturer: Sun Pharma; listing date 2020-08-28 Health Canada: Marketed since 2021-02-22 · brand TARO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95168 · Verify on the e-Formulary ↗ (DIN 02463571)

Source record
DIN 02463571: Taro-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SPC Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02463571 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95168
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931
Shortage status: resolved shortage (ended 2025-11-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02463571
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Gliclazide MR · DIN 02407124 · 60mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Gliclazide MR · DIN 02407124 Manufacturer: Apotex Inc.; listing date 2015-05-28 Health Canada: Marketed since 2015-04-14 · brand APO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Gliclazide MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89182 · Verify on the e-Formulary ↗ (DIN 02407124)

Source record
DIN 02407124: Apo-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id APX Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02407124 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89182
Interchangeable products
Diamicron MR · DIN 02356422 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended 2025-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02407124
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Diamicron MR · DIN 02356422 · 60mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Diamicron MR (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Diamicron MR · DIN 02356422 Manufacturer: Servier Canada Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-12-09 · brand DIAMICRON MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Servier canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84157 · Verify on the e-Formulary ↗ (DIN 02356422)

Source record
DIN 02356422: Diamicron MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SEV Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.2990; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02356422 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84157
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended 2025-02-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02356422
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Gliclazide-MR · DIN 02429772 · 60mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Gliclazide-MR · DIN 02429772 Manufacturer: Jamp Pharma Corporation; listing date 2024-12-30 Health Canada: Marketed since 2024-10-04 · brand JAMP GLICLAZIDE-MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Gliclazide-MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91421 · Verify on the e-Formulary ↗ (DIN 02429772)

Source record
DIN 02429772: Jamp Gliclazide-MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id JPC Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02429772 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91421
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Diamicron MR · DIN 02356422 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended 2026-01-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02429772
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Gliclazide MR · DIN 02423294 · 60mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Gliclazide MR · DIN 02423294 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2017-04-27 Health Canada: Marketed since 2025-04-16 · brand MINT-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Gliclazide MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90800 · Verify on the e-Formulary ↗ (DIN 02423294)

Source record
DIN 02423294: Mint-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id MIN Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02423294 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90800
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Diamicron MR · DIN 02356422 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: resolved shortage (ended 2025-04-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02423294
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Gliclazide MR · DIN 02439328 · 60mg · extended release tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Gliclazide MR · DIN 02439328 Manufacturer: Sun Pharma; listing date 2017-09-28 Health Canada: Marketed since 2021-02-22 · brand TARO-GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Gliclazide MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92369 · Verify on the e-Formulary ↗ (DIN 02439328)

Source record
DIN 02439328: Taro-Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SPC Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439328 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92369
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Diamicron MR · DIN 02356422 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632
Shortage status: resolved shortage (ended 2026-05-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02439328
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Gliclazide · DIN 02245247 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Gliclazide · DIN 02245247 Manufacturer: Apotex Inc.; listing date 2007-06-06 Health Canada: Marketed since 2002-07-02 · brand APO-GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Gliclazide: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69269 · Verify on the e-Formulary ↗ (DIN 02245247)

Source record
DIN 02245247: Apo-Gliclazide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id APX Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245247 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69269
Interchangeable products
Diamicron · DIN 00765996 · not recorded Gliclazide · DIN 02287072 · $0.0931 Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: resolved shortage (ended 2025-10-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245247
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gliclazide · DIN 02287072 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Gliclazide · DIN 02287072 Manufacturer: Sanis Health Inc.; listing date 2011-09-15 Health Canada: Marketed since 2014-06-10 · brand GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Gliclazide: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77250 · Verify on the e-Formulary ↗ (DIN 02287072)

Source record
DIN 02287072: Gliclazide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id SAI Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287072 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77250
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931 Diamicron · DIN 00765996 · not recorded Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287072
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Gliclazide · DIN 02238103 · 80mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Gliclazide · DIN 02238103 Manufacturer: Teva Canada Limited; listing date 2007-06-06 Health Canada: Marketed since 2014-02-11 · brand TEVA-GLICLAZIDE · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Gliclazide: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61497 · Verify on the e-Formulary ↗ (DIN 02238103)

Source record
DIN 02238103: Teva-Gliclazide Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id TEV Source form: Tab; strength: 80mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238103 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61497
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931 Diamicron · DIN 00765996 · not recorded Gliclazide · DIN 02287072 · $0.0931
Shortage status: resolved shortage (ended 2026-02-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238103
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Gliclazide MR · DIN 02524856 · 30mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.Discontinued 2026-07-23 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Gliclazide MR · DIN 02524856 Manufacturer: Sanis Health Inc.; listing date 2022-09-29 Health Canada: Cancelled post market since 2026-07-23 · brand GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101386 · Verify on the e-Formulary ↗ (DIN 02524856)

Source record
DIN 02524856: Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SAI Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524856 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101386
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Sandoz Gliclazide MR · DIN 02461323 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: active shortage (reported 2024-11-01, last updated 2026-01-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524856
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.

Sandoz Gliclazide MR · DIN 02461323 · 30mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued 2026-07-31 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Gliclazide MR · DIN 02461323 Manufacturer: Sandoz Canada Inc.; listing date 2020-07-31 Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 30 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Gliclazide MR: Formulary list price $0.0931/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94883 · Verify on the e-Formulary ↗ (DIN 02461323)

Source record
DIN 02461323: Sandoz Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002025; group id 745; item number 1824; lccId None; manufacturer id SDZ Source form: SR Tab; strength: 30mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0931; ministry $0.0931 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461323 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94883
Interchangeable products
Apo-Gliclazide MR · DIN 02297795 · $0.0931 Diamicron MR · DIN 02242987 · $0.0931 Gliclazide MR · DIN 02524856 · $0.0931 Jamp Gliclazide MR · DIN 02429764 · $0.0931 Mint-Gliclazide MR · DIN 02423286 · $0.0931 Mylan-Gliclazide MR · DIN 02438658 · $0.0931 Taro-Gliclazide MR · DIN 02463571 · $0.0931
Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461323
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.

Gliclazide MR · DIN 02524864 · 60mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.Discontinued 2026-07-23 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Gliclazide MR · DIN 02524864 Manufacturer: Sanis Health Inc.; listing date 2022-09-29 Health Canada: Cancelled post market since 2026-07-23 · brand GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Gliclazide MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101387 · Verify on the e-Formulary ↗ (DIN 02524864)

Source record
DIN 02524864: Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SAI Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524864 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101387
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Diamicron MR · DIN 02356422 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Sandoz Gliclazide MR · DIN 02461331 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: active shortage (reported 2025-03-26, last updated 2026-01-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524864
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-07-23 — choose a marketed DIN from the same-category list.

Sandoz Gliclazide MR · DIN 02461331 · 60mg · extended release tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued 2026-07-31 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Gliclazide MR · DIN 02461331 Manufacturer: Sandoz Canada Inc.; listing date 2017-08-30 Health Canada: Cancelled post market since 2026-07-31 · brand SANDOZ GLICLAZIDE MR · ATC A10BB09 GLICLAZIDE · form Tablet (extended-release) · route Oral · ingredients GLICLAZIDE 60 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Gliclazide MR: Formulary list price $0.0632/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0632 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94884 · Verify on the e-Formulary ↗ (DIN 02461331)

Source record
DIN 02461331: Sandoz Gliclazide MR Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y Item: 682002036; group id 745; item number 1823; lccId None; manufacturer id SDZ Source form: ER Tab; strength: 60mg Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): $0.0632; ministry $0.0632 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461331 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94884
Interchangeable products
Apo-Gliclazide MR · DIN 02407124 · $0.0632 Diamicron MR · DIN 02356422 · $0.0632 Gliclazide MR · DIN 02524864 · $0.0632 Jamp Gliclazide-MR · DIN 02429772 · $0.0632 Mint-Gliclazide MR · DIN 02423294 · $0.0632 Taro-Gliclazide MR · DIN 02439328 · $0.0632
Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461331
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.

Diamicron · DIN 00765996 · 80mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.Discontinued 2022-10-18 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Diamicron · DIN 00765996 Manufacturer: Servier Canada Inc.; listing date 2007-04-02 Health Canada: Cancelled post market since 2022-10-18 · brand DIAMICRON · ATC A10BB09 GLICLAZIDE · form Tablet · route Oral · ingredients GLICLAZIDE 80 MG · company Servier canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Diamicron: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10918 · Verify on the e-Formulary ↗ (DIN 00765996)

Source record
DIN 00765996: Diamicron Raw flags: chronicUseMed=Y, insOH=Y, notABenefit=Y, sec3=Y Item: 682002010; group id 745; item number 1825; lccId None; manufacturer id SEV Source form: Tab; strength: 80mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00765996 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=10918
Interchangeable products
Apo-Gliclazide · DIN 02245247 · $0.0931 Gliclazide · DIN 02287072 · $0.0931 Teva-Gliclazide · DIN 02238103 · $0.0931
Shortage status: discontinued (2022-09-30, reported by SERVIER CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00765996
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2022-10-18 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (68:20:02 Oral Anti-Diabetic Agents) and how they are covered

Matched class: 68:20:02 Oral Anti-Diabetic Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CANAGLIFLOZIN, DAPAGLIFLOZIN, DAPAGLIFLOZIN & METFORMIN, EMPAGLIFLOZIN, EMPAGLIFLOZIN & METFORMIN, LINAGLIPTIN, LINAGLIPTIN & METFORMIN, SAXAGLIPTIN, SAXAGLIPTIN & METFORMIN, SITAGLIPTIN, SITAGLIPTIN & METFORMIN Some products covered without a code (check the product listing): GLYBURIDE, METFORMIN HCL 68:20:02 Oral Anti-Diabetic Agents

GLYBURIDE

· 8 products · General benefit (6), Listed, not a benefit (2) · strengths: 2.5mg, 5mg · Tab

GLIMEPIRIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1mg, 2mg, 4mg · Tab

CANAGLIFLOZIN

· 8 products · General benefit · strengths: 100mg, 300mg · Tab

DAPAGLIFLOZIN

· 22 products · General benefit · strengths: 5mg, 10mg · Tab

DAPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 850mg · Tab

EMPAGLIFLOZIN

· 2 products · General benefit · strengths: 10mg, 25mg · Tab

EMPAGLIFLOZIN & METFORMIN

· 6 products · General benefit · strengths: 5mg & 1000mg, 5mg & 500mg, 5mg & 850mg, 12.5mg & 1000mg, 12.5mg & 500mg, 12.5mg & 850mg · Tab

LINAGLIPTIN

· 1 products · General benefit · strengths: 5mg · Tab

LINAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab

METFORMIN HCL

· 53 products · Off-Formulary Interchangeable, not an ODB benefit (33), General benefit (19), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 500mg, 1000mg, 850mg · ER Tab, Tab

SAXAGLIPTIN

· 6 products · General benefit · strengths: 2.5mg, 5mg · Tab

SAXAGLIPTIN & METFORMIN

· 3 products · General benefit · strengths: 2.5mg & 1000mg, 2.5mg & 500mg, 2.5mg & 850mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 68:20:02 and 6 more
Full class listing Related classes: 68:20:06 Incretin Mimetics, 68:20:10 Insulins (Rapid Acting), 68:20:12 Insulins (Intermediate Acting), 68:20:14 Insulins (Long Acting), 68:20:16 Insulins (Pre-Mixed) Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS Control of hyperglycemia in gliclazide responsive diabetes mellitus of stable, mild, non- ketosis prone, maturity onset or adult type which cannot be controlled by proper dietary management and exercise, or when insulin therapy is not appropriate. https://pdf.hres.ca/dpd_pm/00054463.PDF PM date: December 24, 2019 Source product: TEVA-GLICLAZIDE; DIN 02238103; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Gliclazide MR · DIN 02524856 Shortage status: active shortage (reported 2024-11-01, last updated 2026-01-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524856

Check this DIN again

Sandoz Gliclazide MR · DIN 02461323 Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461323

Check this DIN again

Gliclazide MR · DIN 02524864 Shortage status: active shortage (reported 2025-03-26, last updated 2026-01-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02524864

Check this DIN again

Sandoz Gliclazide MR · DIN 02461331 Shortage status: discontinued (2024-12-06, reported by SANDOZ CANADA INCORPORATED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461331

Check this DIN again

Diamicron · DIN 00765996 Shortage status: discontinued (2022-09-30, reported by SERVIER CANADA INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00765996

Check this DIN again

Other review policies

For Diamicron: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026